Intercept Pharmaceuticals (ICPT) PT Lowered to $134 at RBC Capital, But Remains Positive Into Next Catalysts

November 5, 2019 2:30 PM EST Send to a Friend
RBC Capital analyst Brian Abrahams lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login